EPIX
vs
S&P 500
EPIX
S&P 500
Over the past 12 months, EPIX has underperformed S&P 500, delivering a return of -88% compared to the S&P 500's +12% growth.
Stocks Performance
EPIX vs S&P 500
Performance Gap
EPIX vs S&P 500
Performance By Year
EPIX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ESSA Pharma Inc
Glance View
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.